Fatty liver caused by tamoxifen in patients with non-metastatic breast cancer. Malignant neoplasm of breast of unspecified site, female
Conditions
Interventions
Intervention 1: Intervention group: The patient takes one capsule containing 500 mg of curcumin (produced by Karen Pharma) daily for 6 months. Before the patients enter the study, complete explanation
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Women with non-metastatic breast cancer whose pathology is positive in terms of hormone receptors and are treated with tamoxifen. Normal liver enzymes Not having viral hepatitis Not having a history of alcohol consumption Not using drugs with hepatotoxicity such as methotrexate, amiodarone, valproic acid, anabolic steroids, as well as the use of anticoagulant and antiplatelet drugs. Insensitivity to curcumin drug No history of chemotherapy
Exclusion criteria
Exclusion criteria: The patient's unwillingness to continue the study Having liver diseases during the study The use of drugs with hepatotoxicity such as methotrexate, amiodarone, valproic acid, anabolic steroids, as well as the use of anticoagulant and antiplatelet drugs after the start of the study. Suffering from any related disease and distorting the results during the study Allergic to curcumin drug Development of Metastasis during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fatty liver grade. Timepoint: 6 months. Method of measurement: Ultrasonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver enzyme level. Timepoint: 6 months. Method of measurement: Lab blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Mehrabi Nejad
Esfahan University of Medical Sciences
Outcome results
None listed